Seth Klarman's Baupost Group sold its entire stake in Vaxcyte (PCVX), a clinical-stage vaccine company, during the second quarter of 2026. The influential investment firm divested all 800,000 of its shares in the company, a position that had previously accounted for 0.91% of its reported portfolio. Vaxcyte is focused on developing pneumococcal conjugate vaccines (PCVs) and has several clinical trials underway.
This trade was made public in an SEC 13F filing on August 13, 2026, which discloses positions held as of June 30, 2026. Such filings reveal portfolio changes from the prior quarter and do not reflect an investment firm's current, real-time trading activity. The disclosure coincides with Vaxcyte's ongoing investment in its late-stage clinical trials, with key data expected in late 2026 and early 2027.